NCT00770029 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2 | Biotech Hunter

Enrollment

276

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

Moderate to Severe Glabellar Frown Lines

Interventions

DRUG

IncobotulinumtoxinA (Xeomin) (20 Units)

The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.

DRUG

Placebo

The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).

Trial Locations (8)

27608

Flynn Consulting PLLC, Raleigh

37215

Tennessee Clinical Research Center, Nashville

70006

Coleman William, Meatrie

90069

Skin Care Center, Los Angeles

02467

SkinCare Physicians of Chestnut Hill, Chestnut Hill

V5Z 4E1

Aesthetic Facial Ophtalmology, Vancouver

Carruthers Clinical Research, Vancouver

M5R 3N8

Solish Nowell, Toronto